D. Boral Capital analyst Jason Kolbert lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $2 from $3 and keeps a Buy rating on the shares. The company has executed on back-to-back capital raises that provide $19M in gross proceeds and reinforce its near-term financial runway, the analyst tells investors in a research note. The firm says that while Reviva’s balance sheet is strengthened, the company’s dilution overhang has expanded.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals 27M share Spot Secondary priced at $0.33
- Reviva Pharmaceuticals announces common stock, warrants offering
- Reviva Pharmaceuticals price target lowered to $7 from $14 at Benchmark
- Reviva Pharmaceuticals Advances Schizophrenia Treatment
- Reviva Pharmaceuticals price target lowered to $2 from $5 at Maxim